Compare Cipla with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs PROCTER & GAMBLE HEALTH - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA PROCTER & GAMBLE HEALTH CIPLA/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 33.3 41.4 80.2% View Chart
P/BV x 3.4 4.4 77.4% View Chart
Dividend Yield % 0.5 10.7 4.4%  

Financials

 CIPLA   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    CIPLA
Mar-19
PROCTER & GAMBLE HEALTH
Dec-18
CIPLA/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs6783,549 19.1%   
Low Rs4841,301 37.2%   
Sales per share (Unadj.) Rs198.2511.4 38.8%  
Earnings per share (Unadj.) Rs18.561.3 30.2%  
Cash flow per share (Unadj.) Rs35.074.0 47.3%  
Dividends per share (Unadj.) Rs3.00440.00 0.7%  
Dividend yield (eoy) %0.518.1 2.8%  
Book value per share (Unadj.) Rs186.3927.8 20.1%  
Shares outstanding (eoy) m805.7016.60 4,853.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.94.7 61.8%   
Avg P/E ratio x31.439.6 79.3%  
P/CF ratio (eoy) x16.632.8 50.7%  
Price / Book Value ratio x3.12.6 119.3%  
Dividend payout %16.2717.9 2.3%   
Avg Mkt Cap Rs m468,03140,257 1,162.6%   
No. of employees `00022.61.1 1,996.8%   
Total wages/salary Rs m28,5651,313 2,176.1%   
Avg. sales/employee Rs Th7,053.17,486.7 94.2%   
Avg. wages/employee Rs Th1,261.51,157.6 109.0%   
Avg. net profit/employee Rs Th659.1897.2 73.5%   
INCOME DATA
Net Sales Rs m159,7108,490 1,881.2%  
Other income Rs m4,766244 1,954.0%   
Total revenues Rs m164,4758,734 1,883.2%   
Gross profit Rs m30,9731,482 2,090.5%  
Depreciation Rs m13,263211 6,279.9%   
Interest Rs m1,6840-   
Profit before tax Rs m20,7911,514 1,373.0%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m5,695563 1,012.5%   
Profit after tax Rs m14,9241,017 1,466.9%  
Gross profit margin %19.417.5 111.1%  
Effective tax rate %27.437.1 73.7%   
Net profit margin %9.312.0 78.0%  
BALANCE SHEET DATA
Current assets Rs m124,26615,343 809.9%   
Current liabilities Rs m37,7151,960 1,924.0%   
Net working cap to sales %54.2157.6 34.4%  
Current ratio x3.37.8 42.1%  
Inventory Days Days9149 185.9%  
Debtors Days Days9528 333.5%  
Net fixed assets Rs m105,1901,209 8,698.4%   
Share capital Rs m1,611166 970.7%   
"Free" reserves Rs m148,51115,235 974.8%   
Net worth Rs m150,12315,401 974.8%   
Long term debt Rs m38,3010-   
Total assets Rs m239,63317,595 1,362.0%  
Interest coverage x13.3NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.70.5 138.1%   
Return on assets %6.95.8 119.9%  
Return on equity %9.96.6 150.5%  
Return on capital %11.810.3 115.4%  
Exports to sales %34.70-   
Imports to sales %00-   
Exports (fob) Rs m55,419NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m57,4101,636 3,508.5%   
Fx outflow Rs m19,0414,368 435.9%   
Net fx Rs m38,368-2,732 -1,404.5%   
CASH FLOW
From Operations Rs m16,911-1,304 -1,297.1%  
From Investments Rs m-16,68712,697 -131.4%  
From Financial Activity Rs m-3,487-301 1,160.5%  
Net Cashflow Rs m-3,45111,093 -31.1%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 51.8 40.2%  
Indian inst/Mut Fund % 12.2 18.2 67.0%  
FIIs % 23.7 1.0 2,370.0%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 29.1 90.0%  
Shareholders   161,166 28,591 563.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  ABBOTT INDIA  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Higher; Energy and IT Stocks Witness Buying(Closing)

After opening the day on a strong note, Indian share markets erased most of the gains and turned highly volatile in the afternoon session.

Related Views on News

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

A Warning for Traders: Don't Get Addicted to Hopium(Fast Profits Daily)

Jun 30, 2020

If you are a trader, you must watch out for this dangerous addiction.

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jul 13, 2020 (Close)

TRACK CIPLA

CIPLA - PIRAMAL ENTERPRISES COMPARISON

COMPARE CIPLA WITH

MARKET STATS